27 May 2021 - Upfront costs high but treatments may cut long-term expense and boost patient results.
Irish patients will not be able to access expensive cutting-edge medicines without a rethink of the reimbursement model used to pay for new treatments, according to a report published on Thursday.
Ireland is currently almost alone among western European countries in not granting patients access to modern cell and gene therapy treatments, it says.